Business
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
~ A showcase of PF614 and PF614-MPAR ~SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ A showcase of PF614 and PF614-MPAR ~SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (\"Ensysce\" or \"Company\"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has posted to the Company's Corporate and Investor Relations website a video highlighting its PAINWeek Symposium entitled, \"Severe Pain, Next Generation Solutions: PF614 / PF614-MPAR\" held in Las Vegas on Sept 7, 2023.The \"Highlights Video\" features Dr. Jeff Gudin, University of Miami, School of Medicine Faculty of Anesthesiology and Pain Management, Dr. Richard Dart, Director of the Rocky Mountain Poison and Drug Center, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, three leading authorities on pain, opioid use and drug development, and their perspectives of PF614 and PF614-MPAR treatments as well-positioned to become the ‘next generation' of analgesics.\"We are pleased to share this short summary of the PAINWeek event, attended by over 400 experts in the field. This meeting provided an expansive platform to share the notable clinical progress of our two lead programs which we believe provide the promise of a novel approach to safer solutions for patients in pain.\" said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences.About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.Forward-Looking StatementsStatements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federa...